Lipid Abnormalities
Open Access
- 1 April 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (s2) , S79-S83
- https://doi.org/10.1086/367562
Abstract
Dyslipidemia is an important clinical problem in individuals infected with human immunodeficiency virus (HIV) who are receiving antiretroviral therapKeywords
This publication has 34 references indexed in Scilit:
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Severe premature coronary artery disease with protease inhibitorsThe Lancet, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infectionThe American Journal of Medicine, 1993
- Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndromeJournal of Clinical Endocrinology & Metabolism, 1992